About: Ixazomib Citrate Proteasome Inhibitor Oncolytic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ixazomib Citrate Proteasome Inhibitor Oncolytic Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1835040&p_IsPs=N
Description	Ixazomib citrate, produced and patented by Millennium Pharmaceuticals, is one of the %22new-generation%22 proteasome inhibitors following the success story of the first-in-class proteasome inhibitor bortezomib. Today, bortezomib is approved for multiple myeloma and mantle cell lymphoma, but has failed in clinical trials in patients with solid tumors. According to available preclinical data, ixazomib citrate may be more active in solid tumors. It also appears to be better tolerated by patients, as the most serious adverse event for bortezomib, neuropathy, has not yet been observed in clinical trials with ixazomib citrate. Ixazomib citrate can be administered both intravenously and orally. Ixazomib citrate, produced and patented by Millennium Pharmaceuticals, is one of the %22new-generation%22 proteasome inhibitors following the success story of the first-in-class proteasome inhibitor bortezomib. Today, bortezomib is approved for multiple myeloma and mantle cell lymphoma, but has failed in clinical trials in patients with solid tumors. According to available preclinical data, ixazomib citrate may be more active in solid tumors. It also appears to be better tolerated by patients, as the most serious adverse event for bortezomib, neuropathy, has not yet been observed in clinical trials with ixazomib citrate. Ixazomib citrate can be administered both intravenously and orally. (en)
Title	Ixazomib Citrate Proteasome Inhibitor Oncolytic Ixazomib Citrate Proteasome Inhibitor Oncolytic (en)
skos:prefLabel	Ixazomib Citrate Proteasome Inhibitor Oncolytic Ixazomib Citrate Proteasome Inhibitor Oncolytic (en)
skos:notation	RIV/61989592:15310/12:33141659!RIV13-MSM-15310___
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(EE.2.3.20.0062)
http://linked.open...iv/cisloPeriodika	8
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Cvek, Boris
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Přírodovědecká fakulta
http://linked.open...dnocenehoVysledku	143217
http://linked.open...ai/riv/idVysledku	RIV/61989592:15310/12:33141659
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	profile; resistance; MLN9708; colorectal-cancer; antitumor-activity; peripheral neuropathy; multiple-myeloma; phase-II; single-agent bortezomib; metastatic breast-cancer (en)
http://linked.open.../riv/klicoveSlovo	metastatic breast-cancer peripheral neuropathy MLN9708 antitumor-activity multiple-myeloma single-agent bortezomib colorectal-cancer profile resistance phase-II
http://linked.open...odStatuVydavatele	ES - Španělské království
http://linked.open...ontrolniKodProRIV	[8E3499EC3819]
http://linked.open...i/riv/nazevZdroje	Drugs of the Future
http://linked.open...in/vavai/riv/obor	FR
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	1 (xsd:int)
http://linked.open...vavai/riv/projekt	An inexpensive drug Antabuse as anticancer remedy: mechanism of action and clinical trials
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	37
http://linked.open...iv/tvurceVysledku	Cvek, Boris
http://linked.open...ain/vavai/riv/wos	000311192300003
issn	0377-8282
number of pages	5 (xsd:int)
http://bibframe.org/vocab/doi	10.1358/dof.2012.37.8.1835040
http://localhost/t...ganizacniJednotka	15310

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software